ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.50.

Several equities analysts have weighed in on ALXO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their target price for the company from $12.00 to $2.00 in a research note on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research note on Wednesday, December 18th.

ALX Oncology Stock Down 4.1 %

ALXO stock opened at $1.62 on Monday. The business’s 50-day moving average price is $1.52 and its 200-day moving average price is $3.08. The stock has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Activity

In related news, Director Rekha Hemrajani acquired 30,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of ALX Oncology in the second quarter valued at $63,000. GSA Capital Partners LLP bought a new stake in ALX Oncology in the third quarter worth $88,000. Finally, Barclays PLC increased its position in ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after purchasing an additional 42,185 shares during the last quarter. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.